The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020 The ICR has criticised the decision by NICE not to recommend the immunotherapy, pembrolizumab, as a first-line treatment for patients with advanced head and neck cancer and is calling for an urgent reassessment of the evidence for the drug’s benefit. Find out more Show/Hide
Prostate cancer ‘super responders’ live for two years on immunotherapy 27 Nov 2019 Some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy, a major clinical trial has shown. Find out more Show/Hide
Major trial backs immunotherapy as standard first-line treatment for head and neck cancer 23 Nov 2019 Immunotherapy is better than standard ‘extreme’ chemotherapy as first-line treatment for advanced head and neck cancer and can keep some patients alive for more than three years, a major new trial reports. Find out more Show/Hide
ASCO 2019: Immunotherapy better than aggressive chemotherapy as first treatment option for recurrent head and neck cancer 04 Jun 2019
Immunotherapy keeps some patients with advanced head and neck cancer alive for more than three years 30 Nov 2018
ESMO 2018: Immunotherapy effective as first-line treatment for advanced head and neck cancer 22 Oct 2018
ASCO 2018: Major trial is first to show benefits of immunotherapy in some men with prostate cancer 02 Jun 2018